Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis
Brief Summary: REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy.

The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.


Options:
A: Arm Label: Regimen 1 - 2EHRZ/4HR (control regimen); Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Arm Label: Regimen 2 - 2MHRZ/2MHR; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Arm Label: Regimen 3 - 2EMRZ/2MR; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Intervention Type: DRUG; Name: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin; Assigned to Arm(s): Regimen 1 - 2EHRZ/4HR (control regimen), Regimen 2 - 2MHRZ/2MHR, Regimen 3 - 2EMRZ/2MR
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): 1, 2
C: Arm Label: Arm 1 (R35); Type: EXPERIMENTAL; Interventions: Drug: Rifampicin, Drug: isoniazid, Drug: pyrazinamide, Drug: ethambutol, Dietary Supplement: pyridoxine | Arm Label: HRZQ; Type: EXPERIMENTAL; Interventions: Drug: SQ109, Drug: Rifampicin, Drug: isoniazid, Drug: pyrazinamide, Dietary Supplement: pyridoxine | Arm Label: HR20ZQ; Type: EXPERIMENTAL; Interventions: Drug: SQ109, Drug: Rifampicin, Drug: isoniazid, Drug: pyrazinamide, Dietary Supplement: pyridoxine | Arm Label: HR20ZM; Type: EXPERIMENTAL; Interventions: Drug: Rifampicin, Drug: isoniazid, Drug: pyrazinamide, Dietary Supplement: pyridoxine | Arm Label: HRZE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifampicin, Drug: Moxifloxacin, Drug: isoniazid, Drug: pyrazinamide, Drug: ethambutol, Dietary Supplement: pyridoxine | Intervention Type: DRUG; Name: SQ109; Assigned to Arm(s): HR20ZQ, HRZQ | Intervention Type: DRUG; Name: Rifampicin; Assigned to Arm(s): Arm 1 (R35), HR20ZM, HR20ZQ, HRZE, HRZQ | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): HRZE | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): Arm 1 (R35), HR20ZM, HR20ZQ, HRZE, HRZQ | Intervention Type: DRUG; Name: pyrazinamide; Assigned to Arm(s): Arm 1 (R35), HR20ZM, HR20ZQ, HRZE, HRZQ | Intervention Type: DRUG; Name: ethambutol; Assigned to Arm(s): Arm 1 (R35), HRZE | Intervention Type: DIETARY_SUPPLEMENT; Name: pyridoxine; Assigned to Arm(s): Arm 1 (R35), HR20ZM, HR20ZQ, HRZE, HRZQ
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol | Intervention Type: DRUG; Name: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Isoniazid, Rifampin, Pyrazinamide, Ethambutol; Assigned to Arm(s): 2

Answer: A